Perrigo Looks To Spin Out Or Sell Off Rx Business, But Will Separating Generics Add Value?

Perrigo previously saw value in keeping its prescription pharmaceuticals in-house, but now says it will sell off or spin out the topical generics to focus on its over-the-counter brands. Questions remain about whether the company's generics portfolio is valuable enough to stand alone or attract a buyer.

Perrigo Co. PLC said on Aug. 9 that spinning out or selling its prescription pharmaceuticals will allow the generics business to better capitalize on its unique portfolio, while the company focuses on its over-the-counter medicines, but the value of this proposition isn't immediately clear outside of Perrigo.

The company announced alongside its second quarter earnings that it completed a previously disclosed strategic portfolio review and determined that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

06 Jun 2025

• By Joseph Haas

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.

Santen Sees Potential In Myopia Market After Ryjunea Approval

06 Jun 2025

• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Europe’s Drugmakers Lament EU Pharma Package

05 Jun 2025

• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Bayer Boosted By Third FDA Approval For Nubeqa

04 Jun 2025

• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.